Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.

被引：2
|
作者：
Rahbar, Kambiz
Ahmadzadehfar, Hojjat
Kratochwil, Clemens
Baum, Richard P.
Schmidt, Matthias
Pfestroff, Andreas
Prasad, Vikas
Heinzel, Aelxander
Ruf, Juri
Eveslage, Maria
Boegemann, Martin
Fendler, Wolfgang
Krause, Bernd J.
机构：
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Heidelberg Univ, Dept Nucl Med, Heidelberg, Germany
[4] Zentralklin Bad Berka, Bad Berka, Germany
[5] Univ Cologne, Dept Nucl Med, Cologne, Germany
[6] Univ Marburg, Dept Nucl Med, Marburg, Germany
[7] Charite, Dept Nucl Med, Med Ctr, Berlin, Germany
[8] Univ Aachen, Dept Nucl Med, Aachen, Germany
[9] Univ Freiburg, Dept Nucl Med, Freiburg, Germany
[10] Univ Hosp Muenster, IBKF, Munster, Germany
[11] Univ Munster, Med Ctr, Munster, Germany
[12] Univ Munich LMU, Dept Nucl Med, Munich, Germany
[13] Univ Rostock, Dept Nucl Med, Rostock, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.155
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
155
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
    Mader, Nicolai
    Schoeler, Christina
    Pezeshkpour, Niloufar
    Klimek, Konrad
    Groener, Daniel
    Happel, Christian
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (18)
  • [42] Dual PSMA/FDG PET/CT for assessing eligibility and predicting response in mCRPC patients undergoing 177Lu-PSMA-617 radioligand therapy: A post-VISION analysis
    Babu, Anushna S.
    Tripathi, Madhavi
    Yadav, Madhav
    Ballal, Sanjana
    Satapathy, Swayamjeet
    Bal, Chandrasekhar
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [43] Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
    Rahbar, Kambiz
    Bode, Axel
    Weckesser, Matthias
    Avramovic, Nemanja
    Claesener, Michael
    Stegger, Lars
    Boegemann, Martin
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 522 - 528
  • [44] Analysis of Theranostic 177Lu-PSMA-617 Therapy Efficacy and Toxicity in Patients with Advanced Prostate Cancer
    Zhang, A. Y.
    Bertsch, H. F.
    Chaudhary, A. A.
    Salner, A. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E602 - E603
  • [45] Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Braeuer, Axel
    Yordanova, Anna
    Boegemann, Martin
    Hauser, Stefan
    Eveslage, Maria
    Essler, Markus
    Schafers, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [46] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
    Mair, Christian
    Warwitz, Boris
    Fink, Katharina
    Scarpa, Lorenza
    Nilica, Bernhard
    Maffey-Steffan, Johanna
    Buxbaum, Sabine
    Virgolini, Irene J.
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (07) : 499 - 502
  • [47] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
    Christian Mair
    Boris Warwitz
    Katharina Fink
    Lorenza Scarpa
    Bernhard Nilica
    Johanna Maffey-Steffan
    Sabine Buxbaum
    Irene J. Virgolini
    Annals of Nuclear Medicine, 2018, 32 : 499 - 502
  • [48] Therapeutic efficacy and clinical outcome of 177Lu-PSMA-617/225Ac-PSMA-617 radioligand therapy in metastatic castration resistant prostate cancer (mCRPC) - single institutional experience from India
    Kalra, Kriti
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [49] Study protocol: A randomized phase 2 trial of FLEXible and extended dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy in mCRPC (FLEX-MRT)
    Holzgreve, A.
    Delker, A.
    Ells, Z.
    Brosch-Lenz, J.
    Zhu, S.
    Lira, S.
    Nikitas, J.
    Grogan, T.
    Elashoff, D.
    Unterrainer, L. M.
    Dahlbom, M.
    Allen-Auerbach, M.
    Czernin, J.
    Calais, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S927 - S928
  • [50] 225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand TherapyPilot Experience From a Prospective Registry
    Rosar, Florian
    Burgard, Caroline
    Rohloff, Luna Vanessa
    Blickle, Arne
    Bartholomae, Mark
    Maus, Stephan
    Petto, Sven
    Schaefer-Schuler, Andrea
    Ezziddin, Samer
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : 621 - 629
12345